ORKA
Oruka Therapeutics, Inc.
Price Chart
Latest Quote
$95.81
+5.48 (+6.07%)
Current Price
| Previous Close | $90.33 |
| Open | $89.02 |
| Day High | $96.59 |
| Day Low | $89.02 |
| Volume | 1,205,199 |
Stock Information
| Shares Outstanding | 66.21M |
| Total Debt | $2.55M |
| Cash Equivalents | $873.56M |
| Net Income | $-109.69M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $6.34B |
| EPS (TTM) | $-2.30 |
| Exchange | NGM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $5.11B |
| Income | $-109.69M |
| Book/sh | $18.20 |
| Cash/sh | $13.19 |
| Employees | 68 |
Financial Ratios
| Quick Ratio | 38.03 |
| Current Ratio | 38.51 |
| Debt/Eq | 0.23 |
Returns & Margins
| ROA | -12.95% |
| ROE | -18.23% |
Ownership
| Insider Ownership | 1.26% |
| Institutional Ownership | 116.93% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -33.48 |
| P/B | 5.26 |
Analyst Data
| Recommendation | strong_buy |
| Target Price | $156.17 |
Technical Indicators
| SMA20 | $80.83 |
| SMA50 | $89.24 |
| SMA200 | $68.26 |
| RSI | 68.92 |
| ATR | 4.7300 |
| Shares Float | 56.89M |
| Short Float | 17.10% |
| Short Ratio | 7.87 |
| Volatility | -0.11 |
| Rel Volume | 1.26 |
Performance History
| Week | +21.14% |
| Month | +13.80% |
| Quarter | +8.79% |
| 6 Months | +29.49% |
| YTD | +238.91% |
| Year | +251.60% |
| 3 Years | +631.30% |
| 5 Years | +441.80% |
| 10 Years | -62.51% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-10-27 | $95.81 | 1,205,199 |
| 2026-10-26 | $90.33 | 1,942,700 |
| 2026-10-23 | $80.15 | 514,000 |
| 2026-10-22 | $81.15 | 589,900 |
| 2026-10-21 | $79.92 | 953,400 |
| 2026-10-20 | $79.09 | 787,700 |
| 2026-10-19 | $74.48 | 812,700 |
| 2026-10-16 | $71.93 | 1,388,200 |
| 2026-10-15 | $73.87 | 1,222,100 |
| 2026-10-14 | $76.68 | 685,300 |
| 2026-10-13 | $78.19 | 503,100 |
| 2026-10-12 | $80.35 | 547,900 |
| 2026-10-09 | $82.11 | 1,206,700 |
| 2026-10-08 | $77.28 | 1,225,000 |
| 2026-10-07 | $79.50 | 809,900 |
| 2026-10-06 | $80.18 | 1,122,000 |
| 2026-10-05 | $84.38 | 629,600 |
| 2026-10-02 | $84.52 | 581,500 |
| 2026-10-01 | $83.42 | 921,000 |
| 2026-09-30 | $83.29 | 1,535,600 |
| 2026-09-29 | $82.15 | 1,363,300 |
| 2026-09-28 | $84.19 | 923,300 |
About Oruka Therapeutics, Inc.
Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications. Its lead products include ORKA-001 that targets p19 subunit of interleukin-23, which is in phase 2a trial for the treatment of PsO; and ORKA-002 that targets interleukin-17A and interleukin-17F, which is in phase 2 trial for the treatment of PsO, psoriatic arthritis, and other conditions. The company also develops ORKA-003 for targeting an undisclosed pathway; and ORKA-021, a sequential combination regimen of ORKA-002 and ORKA-001. Oruka Therapeutics, Inc. is headquartered in Menlo Park, California.
đ° Latest News
No news articles available at the moment. Check back later for updates on ORKA.
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 |
|---|---|
| Revenue | |
| Total Revenue | $0 |
| Operating Revenue | $0 |
| Expenses | |
| Interest Expense | $0 |
| Total Expenses | $122,051,000 |
| Other Income Expense | $-12,000 |
| Other Non Operating Income Expenses | $-12,000 |
| Net Non Operating Interest Income Expense | $16,630,000 |
| Interest Expense Non Operating | $0 |
| Operating Expense | $122,051,000 |
| General And Administrative Expense | $21,411,000 |
| Income & Earnings | |
| Net Income From Continuing Operation Net Minority Interest | $-105,433,000 |
| Net Interest Income | $16,630,000 |
| Interest Income | $16,630,000 |
| Normalized Income | $-105,433,000 |
| Net Income From Continuing And Discontinued Operation | $-105,433,000 |
| Total Operating Income As Reported | $-122,051,000 |
| Net Income Common Stockholders | $-105,433,000 |
| Net Income | $-105,433,000 |
| Net Income Including Noncontrolling Interests | $-105,433,000 |
| Net Income Continuous Operations | $-105,433,000 |
| Pretax Income | $-105,433,000 |
| Interest Income Non Operating | $16,630,000 |
| Operating Income | $-122,051,000 |
| Per Share | |
| Diluted EPS | $-1.85 |
| Basic EPS | $-1.85 |
| Other | |
| Tax Effect Of Unusual Items | $0 |
| Tax Rate For Calcs | $0 |
| Normalized EBITDA (Bullshit earnings) | $-105,350,000 |
| Reconciled Depreciation | $83,000 |
| EBITDA (Bullshit earnings) | $-105,350,000 |
| EBIT | $-105,433,000 |
| Diluted Average Shares | $45,614,142 |
| Basic Average Shares | $45,614,142 |
| Diluted NI Availto Com Stockholders | $-105,433,000 |
| Research And Development | $100,640,000 |
| Selling General And Administration | $21,411,000 |
| Other Gand A | $6,379,000 |
| Salaries And Wages | $15,032,000 |
Fetched: 2026-10-19
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Assets | ||
| Net Tangible Assets | $468,999,000 | $379,290,000 |
| Total Assets | $488,617,000 | $396,019,000 |
| Total Non Current Assets | $144,760,000 | $19,150,000 |
| Other Non Current Assets | $103,000 | $43,000 |
| Investmentin Financial Assets | $142,539,000 | $18,069,000 |
| Current Assets | $343,857,000 | $376,869,000 |
| Other Current Assets | $6,813,000 | $1,221,000 |
| Cash Cash Equivalents And Short Term Investments | $337,044,000 | $375,648,000 |
| Cash And Cash Equivalents | $46,935,000 | $61,575,000 |
| Receivables | - | $0 |
| Debt | ||
| Total Debt | $1,932,000 | $968,000 |
| Long Term Debt And Capital Lease Obligation | $1,313,000 | $755,000 |
| Current Debt And Capital Lease Obligation | $619,000 | $213,000 |
| Liabilities | ||
| Total Liabilities Net Minority Interest | $19,618,000 | $16,729,000 |
| Total Non Current Liabilities Net Minority Interest | $4,244,000 | $3,686,000 |
| Current Liabilities | $15,374,000 | $13,043,000 |
| Payables And Accrued Expenses | $9,489,000 | $10,789,000 |
| Payables | $4,164,000 | $9,484,000 |
| Accounts Payable | $4,155,000 | $3,462,000 |
| Equity | ||
| Common Stock Equity | $468,999,000 | $379,290,000 |
| Total Equity Gross Minority Interest | $468,999,000 | $379,290,000 |
| Stockholders Equity | $468,999,000 | $379,290,000 |
| Gains Losses Not Affecting Retained Earnings | $546,000 | $-41,000 |
| Other Equity Adjustments | $546,000 | $-41,000 |
| Retained Earnings | $-189,157,000 | $-83,724,000 |
| Preferred Securities Outside Stock Equity | $2,931,000 | $2,931,000 |
| Preferred Stock Equity | - | $2,931,000 |
| Other | ||
| Ordinary Shares Number | $48,722,309 | $37,440,510 |
| Share Issued | $48,722,309 | $37,440,510 |
| Tangible Book Value | $468,999,000 | $379,290,000 |
| Invested Capital | $468,999,000 | $379,290,000 |
| Working Capital | $328,483,000 | $363,826,000 |
| Capital Lease Obligations | $1,932,000 | $968,000 |
| Total Capitalization | $468,999,000 | $379,290,000 |
| Additional Paid In Capital | $657,561,000 | $463,018,000 |
| Capital Stock | $49,000 | $37,000 |
| Common Stock | $49,000 | $37,000 |
| Long Term Capital Lease Obligation | $1,313,000 | $755,000 |
| Current Capital Lease Obligation | $619,000 | $213,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $5,266,000 | $2,041,000 |
| Current Accrued Expenses | $5,325,000 | $1,305,000 |
| Dueto Related Parties Current | $9,000 | $6,022,000 |
| Investments And Advances | $142,539,000 | $18,069,000 |
| Available For Sale Securities | $142,539,000 | $18,069,000 |
| Net PPE | $2,118,000 | $1,038,000 |
| Gross PPE | $2,118,000 | $1,038,000 |
| Other Properties | $2,118,000 | $1,038,000 |
| Other Short Term Investments | $290,109,000 | $314,073,000 |
| Preferred Stock | - | $2,931,000 |
Fetched: 2026-10-19
Cash Flow Statement (Annual)
| Metric | 2025-12-31 |
|---|---|
| Free Cash Flow | |
| Free Cash Flow | $-88,419,000 |
| Operating Activities | |
| Operating Cash Flow | $-88,210,000 |
| Cash Flow From Continuing Operating Activities | $-88,210,000 |
| Investing Activities | |
| Capital Expenditure | $-209,000 |
| Investing Cash Flow | $-96,745,000 |
| Cash Flow From Continuing Investing Activities | $-96,745,000 |
| Financing Activities | |
| Issuance Of Capital Stock | $671,000 |
| Financing Cash Flow | $170,315,000 |
| Cash Flow From Continuing Financing Activities | $170,315,000 |
| Net Other Financing Charges | $169,644,000 |
| Net Preferred Stock Issuance | $0 |
| Preferred Stock Issuance | $0 |
| Net Common Stock Issuance | $671,000 |
| Common Stock Issuance | $671,000 |
| Other | |
| Issuance Of Debt | $0 |
| End Cash Position | $46,935,000 |
| Beginning Cash Position | $61,575,000 |
| Changes In Cash | $-14,640,000 |
| Net Issuance Payments Of Debt | $0 |
| Net Long Term Debt Issuance | $0 |
| Long Term Debt Issuance | $0 |
| Net Investment Purchase And Sale | $-96,536,000 |
| Sale Of Investment | $424,423,000 |
| Purchase Of Investment | $-520,959,000 |
| Net PPE Purchase And Sale | $-209,000 |
| Purchase Of PPE | $-209,000 |
| Change In Working Capital | $-2,555,000 |
| Change In Other Current Liabilities | $-448,000 |
| Change In Other Current Assets | $-60,000 |
| Change In Payables And Accrued Expense | $1,925,000 |
| Change In Accrued Expense | $7,245,000 |
| Change In Payable | $-5,320,000 |
| Change In Account Payable | $-5,320,000 |
| Change In Prepaid Assets | $-3,972,000 |
| Other Non Cash Items | $-4,545,000 |
| Stock Based Compensation | $24,240,000 |
| Depreciation Amortization Depletion | $83,000 |
| Depreciation And Amortization | $83,000 |
| Depreciation | $83,000 |
| Net Income From Continuing Operations | $-105,433,000 |
Fetched: 2026-10-19